http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-084229-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_132aa5ddba376cda52c2bedb26765245 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-57 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-56 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-565 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-57 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P15-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-565 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-56 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-567 |
| filingDate | 2011-12-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_27b4d62cbb01b32c3c3c288fe0e78bab http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_09427ec027a0d4672f7869f873d80a0f |
| publicationDate | 2013-05-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AR-084229-A2 |
| titleOfInvention | POLYPHASIC PREPARED FOR CONTRACEPTION BASED ON A NATURAL STROGEN |
| abstract | Claim 1: Polyphase preparation for contraception characterized in that the first phase consists of 2 units of daily doses of the natural estrogen, estradiolvalerate, of 3 mg each; the second phase consists of 2 groups of daily dose units where the first group consists of 5 units of daily doses of a combination of 2 mg of estradiolvalerate and at least double or triple the anovulatory dose of a synthetic gestagen, and the second group consists of 17 units of daily doses of a combination of 2 mg of estradiolvalerate and at least three or four times the anovulatory dose of a synthetic gestagen; a third phase of 2 units of daily doses containing 1 mg of estradiolvalerate each; and another phase consisting of 2 units of daily doses of a pharmaceutically safe placebo. Claim 2: Polyphasic preparation according to claim 1, characterized in that the gestagenic active substance is dienogest, drospirenone or a gestagen with at least twice its dose known anovulatory. |
| priorityDate | 2004-04-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 29.